Viviora Lifesciences Private Limited

Viviora Lifesciences Private Limited, established on December 6, 2017, is a private pharmaceutical company headquartered in Pune, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74999PN2017PTC173716. Its authorized and paid-up capital are both ₹100,000. The registered office is located at Plot No 12, Sr No 253/2/2, Tirumala Industrial Estate, Road Rajiv Gandhi IT Park Phase 2, Hinjawadi, Pune, Maharashtra, 411057.

Viviora Lifesciences specializes in the formulation and development of pharmaceutical products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. The company's portfolio includes a diverse range of oral dosage forms, including tablets, capsules, syrups, sachets, injectables, specialized products for cancer treatment, critical care items, and topical preparations.

As of the latest available data, Viviora Lifesciences has reported a total export value of $77,000 USD across seven shipments, exporting two products across two therapeutic categories. The top five products include Ifosfamide ($54,000, Rank #8, 2.2% market share) and Vinblastine ($23,000, Rank #8, 3.1% market share). The primary therapeutic categories are Advanced Oncology (69.8%) and Oncology (30.2%). The company's portfolio is highly concentrated, with the top five products accounting for 100% of its exports.

Viviora Lifesciences operates manufacturing facilities in Pune, Maharashtra, India. The company's registered office is located at Plot No 12, Sr No 253/2/2, Tirumala Industrial Estate, Road Rajiv Gandhi IT Park Phase 2, Hinjawadi, Pune, Maharashtra, 411057. Specific details regarding the capacities and specializations of these facilities are not publicly disclosed.

The company's leadership comprises two directors:

• Revanasiddayya: Director since December 6, 2017.

• Pallavi: Director since December 6, 2017.

Both directors have been associated with Viviora Lifesciences since its inception.

Viviora Lifesciences has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained various regulatory approvals and certifications, such as WHO-GMP, EU-GMP, and MHRA-UK, facilitating market access in these regions.

Viviora Lifesciences has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's products are registered with regulatory authorities in countries like Ethiopia, Ghana, Kenya, Nigeria, and the Philippines, enabling access to these markets.

Viviora Lifesciences demonstrates a diversified geographic strategy by exporting to over 30 countries across various continents. This approach mitigates concentration risk and aligns with the company's mission to provide accessible and sustainable healthcare solutions globally.

Specific details regarding Viviora Lifesciences' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company holds WHO-GMP certification, which may facilitate market access in the United States.

Viviora Lifesciences has obtained WHO-GMP and EU-GMP certifications, indicating compliance with international manufacturing standards. These certifications enhance the company's credibility and facilitate market access in regions requiring such compliance.

Viviora Lifesciences holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers. The company has also secured export No Objection Certificates (NOCs), enabling the export of its products to various international markets.

As of the latest available information, there are no publicly disclosed Form 483 observations, warning letters, or import alerts associated with Viviora Lifesciences. The company maintains a compliant status with regulatory authorities.

Viviora Lifesciences operates in the competitive pharmaceutical export market, focusing on oncology products. While specific competitors are not identified, the company's emphasis on specialized oncology treatments positions it within a niche segment, potentially reducing direct competition.

Viviora Lifesciences' key differentiators include its specialized product portfolio in oncology and critical care, adherence to international manufacturing standards, and a diversified geographic presence. These factors contribute to the company's competitive advantage in the global pharmaceutical market.

Viviora Lifesciences is strategically positioned as a manufacturer and exporter of specialized pharmaceutical products, particularly in oncology and critical care. The company's future outlook includes expanding its product offerings and enhancing its presence in emerging markets to achieve sustainable growth.

Viviora Lifesciences demonstrates a strong track record in pharmaceutical manufacturing, with a focus on oncology and critical care products. The company's export volume and consistency are supported by its adherence to international manufacturing standards and certifications. Reliability indicators include its compliant status with regulatory authorities and a diversified geographic presence.

Importers should verify the following certifications when considering Viviora Lifesciences as a supplier:

• WHO-GMP: Verify through the World Health Organization's official website or contact Viviora Lifesciences directly.

• EU-GMP: Check the European Medicines Agency's database or request certification details from the company.

• MHRA-UK: Consult the UK's Medicines and Healthcare products Regulatory Agency for certification status.

When conducting due diligence on Viviora Lifesciences, consider the following steps:

• Verify Regulatory Certifications: Confirm WHO-GMP, EU-GMP, and MHRA-UK certifications.

• Assess Financial Health: Review the company's financial statements and balance sheets.

• Evaluate Product Portfolio: Examine the range and quality of products offered, focusing on oncology and critical care segments.

• Check Export Records: Assess the company's export history and market presence in target regions.

• Review Compliance History: Ensure the company has no history of regulatory violations or warnings.

Red flags to watch for include discrepancies in certification details, financial instability, limited product range, and a history of regulatory non-compliance.